| Name | Title | Contact Details |
|---|
Biesse Group is a global leader in the design, manufacture, and distribution of machinery, integrated systems, components, and software for processing various materials, including wood, glass, stone, plastic, and metal. Founded in 1969 in Pesaro, Italy, the company has grown into a multinational enterprise with around 4,400 employees and a presence in 12 industrial sites and 39 subsidiaries worldwide. Biesse is listed on the STAR segment of the Italian Stock Exchange and exports 90% of its production. The company offers a wide range of solutions, including CNC machining centers, drilling machines, and automated systems tailored for different materials. Biesse emphasizes innovation and sustainability, investing €14 million annually in research and development and holding over 200-250 patents. Its advanced technologies incorporate AI and IoT, supporting industries such as furniture, construction, automotive, aerospace, and shipbuilding. Biesse also provides training and demonstrations through its global network of showrooms and campuses.
Founded in 1904, the Fédération Internationale de Football Association (FIFA) is the umbrella organisation of its members, currently 211 national football associations. Its main objectives, enshrined in its statutes, are to develop football around the world, to stage international competitions and to protect the integrity of football (against match manipulation, doping etc.). FIFA is composed of a number of political bodies (such as the FIFA Congress and the FIFA Council) and the administration. The highest political position is the FIFA President, elected every four years by FIFAs member associations. The FIFA administration, with more than 800 people from over 60 nations, is based in Zurich. It is run by the Secretary General (CEO). FIFA stages FIFA World Cups™ in various forms such as youth, mens and womens, futsal, beach soccer or club competitions. The mens FIFA World Cup™ is not only the most popular single sporting event in the world but also the financial backbone for FIFA and its efforts to develop football worldwide. The financial success of the FIFA World Cup™ allows FIFA to run a wide range of football development programmes and to provide funds, infrastructure and know-how to its member associations through the FIFA Forward Development Programme. For more information visit our website.
Chesapeake Bank is a community bank located in Kilmarnock, Virginia, serving the Northern Neck and Middle Peninsula regions. Established in April 1900 as Lancaster National Bank, it was founded to support local watermen, oystermen, and fishermen. Over the years, the bank has expanded its services to include farmers and various local businesses, adapting to the needs of the community. The bank offers a variety of banking services, including personal banking options like checking and savings accounts, personal loans, and credit cards. For businesses, Chesapeake Bank provides loans, lines of credit, and cash management services. Additionally, it offers investment services through Chesapeake Wealth Management. Known for its community-focused approach, Chesapeake Bank emphasizes treating customers like neighbors and actively engages in local initiatives.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.